Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 10, 2024
Daily News
May 10, 2024
- Apply Elective Care Scheme to Original Biologics with Biosimilars: Professor to LDP
May 10, 2024
- Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
- Jardiance Positive in Japanese CKD Patients Too: Subgroup Analysis
May 10, 2024
- Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
May 10, 2024
- Takeda’s Operating Profit Dips by More than Half in FY2023
May 10, 2024
- Japan Ethical Drug Sales Down 2.4% in March: Crecon
May 10, 2024
- Keytruda Best-Selling Drug in Japan for 7th Month in April: Encise
May 10, 2024
- Ono CEO Calls for Full Abolition of Spillover Re-Pricing Rule
May 10, 2024
- Ono Crosses 500 Billion Yen in FY2023 Sales, Forxiga Drives 9th Year of Growth
May 10, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…